EBITDA: Income before interest, taxes, depreciation and amortization.
Kiniksa Pharmaceuticals International, plc (KNSA) had EBITDA of $78.78M for the most recently reported fiscal year, ending 2025-12-31.
| Income Statement Financials | |
$677.56M |
|
$59.01M |
|
$77.67M |
|
$599.89M |
|
$600.34M |
|
$77.22M |
|
$11.65M |
|
$88.87M |
|
$88.87M |
|
$59.01M |
|
$59.01M |
|
$59.01M |
|
$59.01M |
|
$77.22M |
|
|
EBITDA |
$78.78M |
74.20M |
|
78.98M |
|
$0.80 |
|
$0.75 |
|
| Balance Sheet Financials | |
$527.18M |
|
$1.94M |
|
$236.46M |
|
$763.63M |
|
$139.18M |
|
-- |
|
$56.84M |
|
$196.03M |
|
$567.61M |
|
$552.36M |
|
$567.61M |
|
76.29M |
|
| Cash Flow Statement Financials | |
$137.99M |
|
$-188.99M |
|
$33.02M |
|
$183.58M |
|
$165.60M |
|
$-17.98M |
|
$37.00M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.79 |
|
-- |
|
-- |
|
-- |
|
-- |
|
88.54% |
|
11.40% |
|
11.40% |
|
11.63% |
|
13.12% |
|
8.71% |
|
$136.42M |
|
-- |
|
-- |
|
-- |
|
0.89 |
|
1.41 |
|
43.45 |
|
8.40 |
|
10.40% |
|
10.68% |
|
7.73% |
|
10.40% |
|
$7.44 |
|
$1.73 |
|
$1.75 |
|